ArticleOrphanet journal of rare diseases2026
Diagnosis of de novo fetal aceruloplasminemia via whole exome sequencing and fetal umbilical blood ceruloplasmin measurement.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAceruloplasminemia is an autosomal recessive disorder, characterized by diabetes mellitus and progressive neurological symptoms, absent of phenotype before delivery. It is caused by mutations in CP, resulting in a deficiency in ceruloplasm. This study sought to diagnose sporadic fetal aceruloplasminemia via whole exome sequencing and plasma ceruloplasm measurement.
methodsAmniotic fluid and cord blood samples were obtained from a 29-year-old woman. Trio-based whole exome sequencing was performed due to right aortic arch and left subclavian artery identified in fetal ultrasound scanning, on the maternal request. Plymerase chain reaction was performed on RNA, extracted from fetal cord blood and peripheral blood of the couple. Fetal cord blood ceruloplasmin, copper, iron and transferrin were determined by enzyme linked immunosorbent assay, nephelometric method and spectrometry, respectively. Ceruloplasmin was detected as control in twelve gestational age-matched normal fetal cord blood samples.
resultsNo cardiac-related variants were identified, but two compound heterozygous CP variants (c.1306 C > T, p.(R436*) and c.3019-17T > G) were incidentally detected in the fetus. The c.1306 C > T p.(R436*) variant was a previously reported pathogenic variant that induced nonsense-mediated mRNA decay. The intronic variant (c.3019-17T > G), predicted by SpliceAI to disrupt splicing, was functionally confirmed to cause exon 18 skipping. Besides, ceruloplasmin concentrations in gestational week-matched healthy fetuses ranged from 2.75 to 56.18 mg/L (median: 14.93 mg/L, IQR: 9.96-21.43 mg/L), while it was undetectable (below the lower limit of detection) in the affected fetus. Copper and iron levels in affected fetus were within normal ranges, while transferrin levels were below the normal threshold.
conclusionsOur findings expanded the spectrum of pathogenic variants in CP and provided new insights into the prenatal diagnosis of the aceruloplasminemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.